Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial-Reference-Cited by-同舟云学术

Risk of cardiovascular mortality with androgen deprivation therapy in prostate cancer: A secondary analysis of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Randomized Controlled Trial

Published:2021-04-27 Issue:13 Volume:127 Page:2213-2221
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Butler Santino S.¹^ORCID,Mahal Brandon A.¹^ORCID,Moslehi Javid J.²,Nohria Anju³^ORCID,Dee Edward C.¹^ORCID,Makkar Rishi¹,Whitbeck Amanda¹,Wangoe Janet¹,Mouw Kent W.¹,Nguyen Paul L.¹,Muralidhar Vinayak¹

Affiliation:

1. Department of Radiation Oncology Dana‐Farber Cancer Institute/Brigham and Women's Hospital Boston Massachusetts

2. Division of Cardiovascular Medicine Department of Vanderbilt University Medical Center Nashville Tennessee

3. Department of Cardiovascular Medicine Dana‐Farber Cancer Institute/Brigham and Women's Hospital Boston Massachusetts

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33486

Reference25 articles.

1. Duration of Androgen Suppression in the Treatment of Prostate Cancer